Nasopharyngeal cancer treatment in China

Nasopharyngeal carcinoma occurs more frequently in southern China and parts of Southeast Asia than in most other regions. Epstein-Barr virus infection is associated with many cases, alongside genetic and environmental factors. Because local teams see this disease routinely, assessment and radiotherapy planning for it are well established in Guangzhou.

Radiotherapy is a central treatment because the nasopharynx sits close to critical structures that make surgery difficult. Depending on stage, systemic therapy may be combined with precision radiotherapy. The appropriate combination is decided after review of pathology, MRI and PET-CT imaging and EBV-related test results.

Send pathology confirming nasopharyngeal carcinoma, head and neck MRI and PET/CT reports with original image files, EBV-related test results when available, and records of any previous radiotherapy or chemotherapy, plus a summary of current symptoms such as hearing changes or nasal bleeding.

Yes. For recurrent disease, the team carefully reviews the previous radiotherapy plan and dose before assessing whether re-irradiation or another approach may be feasible. Previous dose to nearby critical structures is a key safety consideration, and in some cases further radiotherapy is not advisable.

Fees depend on the treatment plan, including the radiotherapy course, planning imaging and any combined systemic therapy. After a free initial record check, the hospital provides an itemised written estimate before you make any travel decision. No payment is requested before you accept the plan.

No. Outcomes vary by diagnosis, stage and individual condition, and no result can be promised in advance. If treatment here is not appropriate, the team will explain the alternatives they assessed, or say honestly if treatment here is not recommended.